Association of pre-treatment lymphocyte-monocyte ratio with survival outcome in patients with head and neck cancer treated with chemoradiation.
HN cancer
HPV
LMR
Lymphocyte
Monocyte
chemoRT
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
21 Jun 2023
21 Jun 2023
Historique:
received:
28
02
2023
accepted:
13
06
2023
medline:
23
6
2023
pubmed:
22
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
Given the role of systematic inflammation in cancer progression, lymphocyte-monocyte ratio (LMR) from peripheral blood has been suggested as a biomarker to assess the extent of inflammation in several solid malignancies. However, the role of LMR as a prognostic factor in head and neck cancer was unclear in several meta-analyses, and there is a paucity of literature including patients in North America. We performed an observational cohort study to evaluate the association of LMR with survival outcomes in North American patients with head and neck cancer. A single-institution, retrospective database was queried for patients with non-metastatic head and neck cancer who underwent definitive chemoradiation from June 2007 to April 2021 at the Roswell Park Comprehensive Cancer Center. Primary endpoints were overall survival (OS) and cancer-specific survival (CSS). The association of LMR with OS and CSS was examined using nonlinear Cox proportional hazard model using restricted cubic splines (RCS). Cox multivariable analysis (MVA) and Kaplan-Meier method were used to analyze OS and CSS. Pre-radiation LMR was then stratified into high and low based on its median value. Propensity scored matching was used to reduce the selection bias. A total of 476 patients met our criteria. Median follow up was 45.3 months (interquartile range 22.8-74.0). The nonlinear Cox regression model showed that low LMR was associated with worse OS and CSS in a continuous fashion without plateau for both OS and CSS. On Cox MVA, higher LMR as a continuous variable was associated with improved OS (adjusted hazard ratio [aHR] 0,90, 95% confidence interval [CI] 0.82-0.99, p = 0.03) and CSS (aHR 0.83, 95% CI 0.72-0.95, p = 0.009). The median value of LMR was 3.8. After propensity score matching, a total of 186 pairs were matched. Lower LMR than 3.8 remained to be associated with worse OS (HR 1.59, 95% CI 1.12-2.26, p = 0.009) and CSS (HR 1.68, 95% CI 1.08-2.63, p = 0.02). Low LMR, both as a continuous variable and dichotomized variable, was associated with worse OS and CSS. Further studies would be warranted to evaluate the role of such prognostic marker to tailor interventions.
Sections du résumé
BACKGROUND
BACKGROUND
Given the role of systematic inflammation in cancer progression, lymphocyte-monocyte ratio (LMR) from peripheral blood has been suggested as a biomarker to assess the extent of inflammation in several solid malignancies. However, the role of LMR as a prognostic factor in head and neck cancer was unclear in several meta-analyses, and there is a paucity of literature including patients in North America. We performed an observational cohort study to evaluate the association of LMR with survival outcomes in North American patients with head and neck cancer.
METHODS
METHODS
A single-institution, retrospective database was queried for patients with non-metastatic head and neck cancer who underwent definitive chemoradiation from June 2007 to April 2021 at the Roswell Park Comprehensive Cancer Center. Primary endpoints were overall survival (OS) and cancer-specific survival (CSS). The association of LMR with OS and CSS was examined using nonlinear Cox proportional hazard model using restricted cubic splines (RCS). Cox multivariable analysis (MVA) and Kaplan-Meier method were used to analyze OS and CSS. Pre-radiation LMR was then stratified into high and low based on its median value. Propensity scored matching was used to reduce the selection bias.
RESULTS
RESULTS
A total of 476 patients met our criteria. Median follow up was 45.3 months (interquartile range 22.8-74.0). The nonlinear Cox regression model showed that low LMR was associated with worse OS and CSS in a continuous fashion without plateau for both OS and CSS. On Cox MVA, higher LMR as a continuous variable was associated with improved OS (adjusted hazard ratio [aHR] 0,90, 95% confidence interval [CI] 0.82-0.99, p = 0.03) and CSS (aHR 0.83, 95% CI 0.72-0.95, p = 0.009). The median value of LMR was 3.8. After propensity score matching, a total of 186 pairs were matched. Lower LMR than 3.8 remained to be associated with worse OS (HR 1.59, 95% CI 1.12-2.26, p = 0.009) and CSS (HR 1.68, 95% CI 1.08-2.63, p = 0.02).
CONCLUSION
CONCLUSIONS
Low LMR, both as a continuous variable and dichotomized variable, was associated with worse OS and CSS. Further studies would be warranted to evaluate the role of such prognostic marker to tailor interventions.
Identifiants
pubmed: 37344761
doi: 10.1186/s12885-023-11062-3
pii: 10.1186/s12885-023-11062-3
pmc: PMC10286492
doi:
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
572Subventions
Organisme : NCI NIH HHS
ID : P30 CA016056
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016056
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
JAMA Netw Open. 2022 Apr 1;5(4):e227567
pubmed: 35426920
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Medicine (Baltimore). 2018 Jun;97(26):e11138
pubmed: 29952958
Virology. 2013 Sep;444(1-2):257-62
pubmed: 23871219
J Natl Cancer Inst. 2007 May 16;99(10):777-89
pubmed: 17505073
Cell Immunol. 2014 Nov-Dec;292(1-2):70-7
pubmed: 25460081
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Lancet. 2005 Sep 17-23;366(9490):991-8
pubmed: 16168781
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Stat Med. 1989 May;8(5):551-61
pubmed: 2657958
JAMA. 2015 Oct 20;314(15):1637-8
pubmed: 26501539
Signal Transduct Target Ther. 2021 Jul 12;6(1):263
pubmed: 34248142
Oncotarget. 2016 May 31;7(22):31926-42
pubmed: 26942464
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
Cancer. 2020 Apr 1;126(7):1424-1433
pubmed: 31930488
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
JAMA Netw Open. 2022 Dec 1;5(12):e2245818
pubmed: 36480200
World J Clin Oncol. 2012 Apr 10;3(4):57-62
pubmed: 22553505
Eur Arch Otorhinolaryngol. 2018 Jul;275(7):1663-1670
pubmed: 29651542
Head Neck. 2017 Feb;39(2):247-253
pubmed: 27617428
Oral Maxillofac Surg Clin North Am. 2014 May;26(2):123-41
pubmed: 24794262
Stat Med. 2010 Apr 30;29(9):1037-57
pubmed: 20087875
Crit Rev Oncol Hematol. 2017 Aug;116:134-146
pubmed: 28693795
Cancers (Basel). 2021 Aug 19;13(16):
pubmed: 34439320
BMC Gastroenterol. 2018 Oct 11;18(1):148
pubmed: 30305076
Radiother Oncol. 2021 Jan;154:76-86
pubmed: 32941957
Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):541-50
pubmed: 19190158
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18584-18589
pubmed: 31462499